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Article summary  
• Surgery-associated bleeding risk is high in inherited platelet disorders, especially in 
inherited platelet function disorders, and varies according to diagnosis and procedure  
• Antihemorrhagic pre-operatory prophylaxis prevents excessive bleeding in most cases in 
























Excessive bleeding at surgery is a feared complication in patients with inherited platelet disorders, 
however very few studies have evaluated the frequency of surgical bleeding in these hemorrhagic 
disorders. We performed a multicentric, retrospective worldwide study to assess the bleeding 
complications of surgery, the preventive and therapeutic approaches adopted and their efficacy in 
patients with inherited platelet disorders by rating the outcome of 829 surgical procedures carried 
out in 423 patients with well defined forms of inherited platelet disorders (238 inherited platelet 
function disorders and 185 inherited platelet number disorders). Frequency of surgical bleeding was 
high in patients with inherited platelet disorders (19.7%), with a significantly higher bleeding 
incidence in inherited platelet function disorders (24.8%) than in inherited platelet number disorders 
(13.4%). The frequency of bleeding varied according to the type of inherited platelet disorders, with 
biallelic Bernard Soulier syndrome having the highest occurrence (44.4%), and was predicted by a 
preoperative World Health Organization’s bleeding score ≥2. Some types of surgery were 
associated with a higher bleeding incidence, like cardiovascular and urologic surgery. The use of 
preoperative prohemostatic treatments was associated with a lower bleeding frequency in patients 
with inherited platelet function disorders but not in inherited platelet number disorders. 
Desmopressin, alone or with antifibrinolytic agents, was the preventive treatment associated with 
lowest bleedings. Platelet transfusions were used more frequently in patients at higher bleeding risk. 
Surgical bleeding risk in inherited platelet disorders is substantial, especially in inherited platelet 
function disorders, and bleeding history, type of disorder, type of surgery and female gender are 
associated with higher bleeding frequency. Prophylactic preoperative prohemostatic treatments 




Inherited platelet disorders (IPDs) are a heterogeneous group of bleeding diseases of variable 
clinical severity associated with a reduction of platelet number (inherited platelet number disorders, 
IPNDs) and/or function (inherited platelet function disorders, IPFDs). Spontaneous hemorrhages 
are mainly mucocutaneous and rarely serious, while the hemorrhagic risk of trauma or surgery is 
not well defined1-3. 
Excessive bleeding at surgery is a feared complication of IPDs and is empirically prevented or 
treated with platelet transfusions, antifibrinolytic agents, desmopressin, or recombinant activated 
factor VII (rFVIIa), although evidence of the effectiveness of these measures is mostly anecdotal4-7. 
Two recent international collaborative studies have assessed the delivery-associated bleeding risk 
and pregnancy outcome in a large series of patients with well-defined forms of IPNDs or IPFDs and 
have shown that delivery-related maternal bleeding was more frequent in IPDs than in healthy 
pregnant women and that the degree of thrombocytopenia and history of severe bleeding were 
predictive of delivery-related hemorrhagic risk8,9.  
Although guidelines for the management of bleeding and of invasive procedures in patients with 
platelet disorders and/or thrombocytopenia have been generated10,11 they were not based on 
objective data on the incidence of surgery-related bleeding, and thus were necessarily rather generic. 
Indeed, very few studies on surgery in IPDs have been carried out. One retrospective study 
including 44 children with mild bleeding disorders undergoing adeno-tonsillar procedures, among 
which 27 with an unspecific platelet function disorder, concluded that prophylactic treatment with 
desmopressin and tranexamic acid is effective in preventing perioperative bleeding12. Another 
retrospective study in 113 patients with congenital hemostatic disorders undergoing general surgery 
or endoscopic procedures, including five with platelet disorders, showed low morbidity and 
mortality rates with desmopressin pretreatment13. 
With regard to well defined IPFDs, surgery outcome was described mostly in case reports of 
patients with Glanzmann thrombasthenia (GT), Bernard Soulier syndrome (BSS), or Hermansky-
Pudlak syndrome (HPS). Platelet transfusion for major surgery and antifibrinolytics for minor 
invasive procedures were reported as effective prophylactic measures for GT14-16. Surgery-related 
bleeding, when occurred, was successfully treated with rFVIIa17-19 or platelet transfusions15. Platelet 
transfusions, alone or in combination with antifibrinolytics20-22 or desmopressin 22, prevented 
bleeding in BSS patients, while platelet transfusions, alone23 or in combination with rFVIIa24, were 
used for HPS patients. However, no data on the rate of bleeding complications and its prevention 
can be drawn from these studies. 
Concerning the prevention and treatment of surgical bleeding, the largest experience reported so far 
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is the recent evaluation of rFVIIa effectiveness and safety in 96 GT patients from an international 
observational registry, showing that rFVIIa, administered alone or together with platelet 
transfusions and/or antifibrinolytics, was effective for both minor and major surgery25.  
With regard to IPNDs, platelet transfusions and more recently eltrombopag have been reported to 
successfully prevent bleeding without side-effects in a few MYH9-related disease (MYH9-RD) 
patients26-28.  
Aim of the SPATA (Surgery in Platelet disorders And Therapeutic Approach) study was to evaluate 
the bleeding complications associated with surgical procedures, the therapeutic approaches adopted 
for the prevention and treatment of hemorrhage, and their efficacy in a large series of IPD patients 
diagnosed according to well-defined, standardized criteria and undergoing a wide range of invasive 
procedures. Here we report the results of the analysis of the outcome of 829 surgical interventions 




This study was promoted by the Scientific Working Group (SWG) on Thrombocytopenias and 
Platelet Function Disorders of the European Hematology Association (EHA). The Institutional 
Review Board of the coordinating center (CEAS Umbria, Italy) approved the study, each center 
complied with local ethical rules and all patients or their legal representatives signed a written 
informed consent.  
Participating investigators were asked to review their records and extract data on surgery and 
invasive procedures carried out in patients with IPDs over the last years (median eight; IQR four-18 
years) and to obtain additional data directly from the surgeon who carried out the intervention or, in 
case this was not possible, from the patient or his/her relatives. Only patients with a definite 
diagnosis of IPD confirmed according to well-defined laboratory and/or molecular genetic 
criteria6,8-9 (supplementary table 1 and 2) were eligible for the study. IPDs were subdivided in 
IPNDs, when low platelet count was the main phenotypic characteristic (e.g. MYH9-RD), and 
IPFDs, when platelet dysfunction was the dominant phenotypic feature independently of platelet 
count (e.g. autosomal dominant GT-variant) (Table 1). Patients with acquired platelet disorders of 
any aetiology were excluded. All types of surgical procedures, including invasive diagnostic 
procedures (e.g. angiography, endoscopic and tissue biopsies) and dental extractions, were included. 
Caesarian sections were excluded because analysed in a previous study8,9.  
Surgical procedures were categorized post hoc as major surgery, minor invasive procedures and 
dental procedures according to the following criteria: major, any procedure in which a body cavity 
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was entered, a mesenchymal barrier was crossed, a facial plane was opened, an organ was removed 
or normal anatomy was altered; minor invasive, any operative procedure in which only skin, 
mucous membranes or superficial connective tissue were manipulated, gastroscopy, colonoscopy 
and similar; dental, i.e. extraction, abscess removal, apicectomy and similar25.  
 
Classification of bleeding 
Bleeding history was assessed by the World Health Organization (WHO) bleeding assessment 
scale29 and, when available, by the ISTH bleeding score scale30. Severity of surgical bleeding was 
defined according to three different criteria: the bleeding academic research consortium (BARC) 
classification, considering as excessive any bleeding with a BARC ≥231; a subjective evaluation 
from the surgeon or, when not available, from the patient8,9; and duration (from less than six hours 
to more than three days), considered as excessive when >6 hours. Procedures associated with 
excessive bleeding according to any of the above three criteria were classified as any excessive 
bleeding (AEB).  
When available, maximal drop of haemoglobin after surgery (g/dl) was registered.  
Outcome of treatment of surgical bleeding was classified as successfully controlled, not responsive 
or re-bleeding.  Not responsive was an excessive bleeding episode that the treatment(s) applied 
were not able to stop. Re-bleeding indicates a new episode of bleeding occurring at a later time 
point after the procedure. 
 
Statistical analysis 
Data are reported as medians and 25th-75th percentiles (IQR) when continuous and as counts and 
percentages when categorical. Logistic regression was used to assess the association between 
patient or surgery characteristics with bleeding outcome. Chi-square test and Cochran-Armitage's 
Trend Test were used to compare categorical data. The R software (R Foundation for Statistical 
Computing, Vienna, Austria. www.R-project.org) was used for all analyses. A two-sided p<0.05 
was considered as statistically significant. 
 
RESULTS  
Patients’ characteristics  
Four hundred and twenty three patients (age 2 to 91 years; median 40; IQR 23.7-54; 56% females), 
with 25 different forms of IPDs (16 IPFDs and 9 IPNDs) enrolled by 49 centers across 17 countries 
underwent a total of 829 surgical procedures. Two hundred and thirty eight (56.3%; median age 36 
years; 58% females), for a total of 455 procedures, had an IPFD and 185 (43.7%; median age 43 
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years; 53.5% females), for a total of 374 procedures, an IPND. Diagnosis and baseline 
characteristics are reported in table 1. In order of frequency IPFDs were GT, primary secretion 
defect, biallelic BSS (bBSS), δ granule deficiency, HPS, Gray platelet syndrome (GPS) and 
autosomal dominant GT-variant; while IPNDs in order were MYH9-related disorder, ANKRD26-
related thrombocytopenia, monoallelic BSS (mBSS), ACTN1-related thrombocytopenia. Bleeding 
history was on average mild (WHO grade median 2, IQR 1-3), but 25% of patients had a WHO 
grade 3 (79.8% of which were IPFD) and 3.3% a WHO grade 4 (64.3% of which were IPFD) 
(supplementary figure 1). Thrombocytopenia in IPNDs was on average mild (median 68x109/L; 
IQR 30-81 x109/L) but 50% of patients had a platelet count <50x109/L and 25% <30x109/L. The 
ISTH BAT bleeding score was available for 143 patients (33.5%), with a median score of 3 in the 
overall IPD population (IQR 1-7), 6 (IQR 2-11.25) for IPFD (n=89) and 1 (IQR 0-1) for IPND 
(n=54). 
 
Type of surgery and prophylactic treatments 
Procedures were for 59.7% major surgeries, 28.1% dental and 12.2% minor invasive. Among major 
surgeries the most frequent procedures were abdominal (15.2%), otorhinolaryngologic (12.8%), 
gynecologic (6.8%) and orthopedic (6.8%). Median age at surgery was 31 years for both IPFDs 
(IQR 15-52) and IPNDs (IQR 14-47.5). In IPND, median platelet count at surgery was 56x109/L 
(IQR 40-93). Table 2 summarizes the characteristics of surgical procedures according to IPD 
diagnosis.  
An anti-hemorrhagic prophylactic preoperative treatment was administered in 57.2% of the 
procedures, in particular in 80.6% of procedures in patients with IPFDs and in 20.6% of procedures 
in IPNDs. Frequency of use of preoperative prophylaxis was independent of type of the surgery, in 
fact for IPFDs 77.4% of major surgeries, 87.7% of minor invasive procedures and 82.8% of dental 
procedures were treated; for IPNDs 28.7%, 35.7% 26.3% respectively. On the contrary 
administration of a prophylactic treatment was positively correlated with preoperative WHO 
bleeding score (Cochran-Armitage trend test p<0.0001) (Figure 1A). Moreover, among IPNDs the 
use of prophylactic pro-haemostatic treatment was negatively associated with platelet count 
quartiles (Cochran-Armitage trend test p<0.0001) (Figure 1B).  
Most frequently used prophylactic treatments were platelet transfusions (26.8% for IPFDs and 
20.6% for IPNDs), followed by antifibrinolytic agents (11.2% for IPFDs and 4% for IPNDs), a 
combination of both (12.3% for IPFDs and 1.3% for IPNDs), desmopressin (8.1% for IPFDs and 
1.1% IPNDs), desmopressin with antifibrinolytic agents (7.9% for IPFDs and 0% in IPND) and 
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FVIIa (5.9% for IPFDs and 0% for IPNDs) (Table 3). The use of prophylactic treatments according 
to diagnosis is reported in Table 4. 
Platelet transfusions consisted of fresh platelets from random donors in 97.1% of cases, 34.2% of 
which HLA-matched, and of cryopreserved platelets in 2.9% of the procedures. In IPNDs platelet 
transfusions were used more frequently in patients with platelet counts ≤50 x109/L (OR 2.73, 95% 
CIs 1.63-4.61, p=0.0001) and in those undergoing major surgery (OR 1.94, 95% CIs 1.10-3.42, 
p=0.02), while in IPFDs they were used more frequently in patients with a WHO≥2 (OR 2.22, 95% 
CIs 1.37-3.59 p=0.001) and in those undergoing major surgery (OR 1.45, 95% CIs 1-2.12, p=0.051).  
 
Bleeding outcome  
Excessive bleeding after surgery occurred in 163 of the surgical procedures in the overall IPD 
population (19.7%), when assessed by any of the predefined criteria (i.e. AEB), i.e. 1 episode of 
bleeding every 5 procedures. Excessive bleeding occurred in 15.3% of the procedures when scored 
as ≥2 by the BARC classification, in 15.3% when assessed by subjective evaluation and in 10.5% 
when defined by a duration ≥ 6 hours (supplementary Figure 2). 
When the two populations were analyzed separately, AEB was reported almost twice as frequently 
in IPFDs, who suffered AEB in 24.8% of the procedures, than in IPNDs, for whom AEB was 
reported in 13.4% of the procedures. Haemoglobin drop was 1.29 g/dL (95% CIs 0.89-1.68) for 
IPFD (n=83), and 0.53 g/dL (95% CIs 0.17-0.89) for IPND (n=30) (p=0.005). 
Among IPFDs, AEB was reported more frequently in bBSS (44.4%), FPD/AML (30.7%), GT 
(29.1%), HPS (27.3%), GPS (23.5%) and autosomal-dominant GT-variant (22.7%) than in the 
overall IPFD population. bBSS and GT patients received pre-operative prophylactic treatment in 
97.2% and 90.6% of procedures, respectively, emphasizing the perceived high surgical bleeding 
risk associated with these disorders.  
Among IPNDs, AEB was reported more frequently in MYH9-RD patients (15.5%) than in the 
overall IPND population. The distribution of bleeding outcomes in the individual IPDs is shown in 
supplementary Table 3.  
Frequency of excessive bleeding in the overall IPD population was 21.8% after major surgery, 
23.8% after minor invasive procedures and 13.3% after dental procedures, (for IPFDs 28.6%, 
28.8% and 15.7%, respectively, and for IPNDs 15%, 10.7% and 10.1%).  
In the overall IPD population, AEB was reported more frequently after cardiovascular surgery 
(47.1%), followed by urological (34.2%), gynaecologic (26.8%), otorhinolaryngologic (24.5%), 
plastic (21.4%), eye (20%), and abdominal (19.8%) surgery. Incidence of bleeding in the different 
IPD populations according to the type of surgery is shown in Table 5.   
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AEB, occurring during the first procedure was a risk factor for the recurrence of bleeding during a 
second (IPFD: OR 6.7, 95% CI 2.3-18.9, p=0.0004; IPND: OR 3.82, 95% CI 1.09-13.4, p=0.0357) 
or third procedure (IPFD: OR 10, 95% CI 1.1-90.6, p=0.04; IPND: OR 27, 95% CI 2.2-324.9, 
p=0.0094). 
 
Characteristics associated with post surgical bleeding 
A significant association was found between the frequency of AEB and clinical bleeding history 
assessed by the WHO bleeding score, both in the overall IPD population (WHO 1=OR 2.6; 95% 
CIs 1.0-6.9; WHO 2=OR 5.7; 95% CIs 2.4-13.6; WHO 3=OR 11.2; 95% CIs 4.7-26.7; WHO 4=OR 
17.5; 95% CIs 5.6-54.7) and in the two populations analysed separately (Figure 2A, Table 6).The 
association between the WHO bleeding score and AEB remained also when procedures were 
subdivided in major, minor invasive and dental (Figure 2B).  
Among IPFDs, a higher frequency of postsurgical bleeding was observed in females (Table 6). To 
exclude that this might be due to the relatively high bleeding rate associated with gynaecological 
procedures, we re-evaluated the association between sex and AEB after excluding gynaecological 
procedures. Results confirmed that female sex is a risk factor for postsurgical bleeding in IPFDs 
(OR 1.70 (1.05-2.77), p=0.03).  
A higher frequency of postsurgical bleeding was observed in some disorders, like bBSS, GT and 
HPS (supplementary Table 4).  
Finally, in IPND a platelet count below the median (68x109/L) and an age ≥70 were associated with 
a significantly higher frequency of post-surgical bleeding (table 4).  
 
Efficacy of prophylactic treatments 
The use of a prophylactic anti-hemorrhagic preparation was associated with a markedly reduced 
frequency of surgical bleeding in IPFDs (OR 0.38; 95% CIs 0.23-0.63) (Table 6). 
Indeed, AEB was reported more frequently in patients not receiving a prophylactic treatment than in 
those receiving it (40.9% vs 21%, p<0.01).  
Post-surgical bleeding was lowest in desmopressin-treated patients (AEB in 8.1% of procedures, 
OR 0.13; 95% CIs 0.04-0.45, as compared with no treatment), followed by desmopressin and 
antifibrinolytic agents (8.3%, OR 0.13; 95% CIs 0.04-0.46), antifibrinolytic agents alone (17.6%, 
OR 0.31; 95% CIs 0.13-0.71), antifibrinolytic agents and platelet transfusions (17.8%, OR 0.31; 
95% CIs 0.14-0.70), and rFVIIa (18.5%, OR 0.33; 95% CIs 0.11-0.95). Platelet transfusions alone, 
the majority of which however were given to patients with WHO≥3 (86.8%) and/or undergoing 
major surgery (68.4%), were not associated with a lower frequency of AEB (31.1%). 
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Information about platelet transfusion modalities was obtained for 123 out of 276 procedures in 
which these were used. The median platelet transfusion dose was 4 units (2-8), significantly higher 
in IPFDs (5; 4-8) that in IPNDs (2.5; 1-4) (p=0.0007). The median time of administration before the 
procedure was 1 hour (range few minutes to 3 days). Among GT patients, the dose of platelet 
transfusions was recorded in 58 procedures: AEB was reported in 12 of them (20.7%) and occurred 
more frequently when the amount of platelets transfused was <6 units (9/12, 75%) than when it was 
>6 units (3/12; 25%) (p=0.04 by χ2). Moreover, information about platelet refractioness and/or 
antiplatelet antibody positivity was obtained for 42 GT patients undergoing 143 invasive procedures 
prophylaxed with platelet transfusions. The bleeding rate (AEB) was 23.3% in those without and 
37.5% in those with a history of platelet refractoriness or anti-platelet antibodies (p=ns).  
Differently from IPFDs, prophylactic treatments did not seem to modify surgery-related bleeding 
frequency in IPNDs, since, indeed, AEB was reported in 12.7% of the procedures carried out 
without preparation (34/267) and in 14.9% of the procedures carried out with pre-operative 
prophylaxis (16/107). But actually, antifibrinolytic agents were associated with a lower post-
surgical bleeding frequency in IPNDs (AEB in 6.7% of procedures), while other treatments were 
not. In particular, platelet transfusions were not associated with lower post-surgical bleeding, 
although it must be considered that they were mainly given to patients undergoing major surgery.  
 
Treatment of bleeding and outcome  
Surgical procedures followed by AEB received an emergency treatment in 86.7% of the cases 
(98/113) for IPFDs (platelet transfusions 60.2%, antifibrinolytic agents 17.3%, other 11.2%, FVIIa 
6.1%), and in 62% for IPNDs (31/50) (other 41.9%, platelet transfusions 38.7%, and antifibrinolytic 
agents 19.3%). Treatment of bleeding according to disorder and type of surgery is reported in 
supplementary Table 4. Successful control was obtained in 73.4% of IPFDs and in 58% of IPNDs. 
The most effective treatments were antifibrinolytic agents (88.2% of bleedings controlled, 15/17), 
platelet transfusions (83% of bleedings controlled, 49/59), and other treatments (fresh frozen 
plasma, stitches, ice, compression and dressing) (100% of bleedings controlled, 10/10) for IPFDs, 
while they were platelet transfusions (100% of bleedings controlled, 12/12), followed by other 
treatments (surgical hemostasis, packing, compression, stitches) (92.3% of bleedings controlled, 
12/13), and antifibrinolytic agents (83.3% of bleedings controlled, 5/6) for IPNDs.  
In 21 procedures carried out in 18 patients (12.9% of the procedures with AEB) outcome of 
bleeding was unfavorable (19 re-bleeding, 2 not responding to treatment). Of these, 80.9% occurred 
in IPFD (12 GT, 1 bBSS, 1 primary secretion defect, 1 CalDAG-related platelet disorder, 1 GPS, 1 
defect of TP receptor) and 19.1% in IPNDs (3 MYH9-RD, 1 ANKRD-26 related 
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thrombocytopenia). Among these patients, one had a WHO=0, nine a WHO =2, 10 a WHO= 3 and 
1 a WHO=4. The majority of these procedures (15) were major surgeries, but 3 were colonoscopy 
with polypectomy, 2 dental procedures and one an enteroscopy for an angiodysplasia and in 76.2% 
of them prophylaxis had been administered before surgery.  Re-bleeding was treated mainly with 
platelet transfusions and/or antifibrinolytic agents and resolved in all but two cases, a 32 year old 
man with GT undergoing partial lung resection for recurrent severe hemoptysis and a 51 year old 
man with MYH9-RD undergoing endovascular treatment of an intracranial aneurysm for whom the 
outcome was death. 
 
DISCUSSION 
Although IPDs are conventionally considered as rare, annually at least 14,000 patients worldwide 
undergo investigations for a suspected IPD and over 5,600 new diagnoses are made2. It is therefore 
not an unexpected evenience that a surgeon may deal with a patient with an IPD, and the knowledge 
of the bleeding risks associated with the distinct invasive procedures and the different platelet 
disorders may be of great help to guide surgical management.  
Our study with 829 surgical procedures in 423 patients represents the largest experience reported so 
far on surgery in patients with IPDs. 
It turns out that the frequency of excessive bleeding associated with surgery in patients with IPD is 
substantial, varying from 9.9% to 19.7% depending on the definition used. In particular, it strikingly 
emerges that bleeding frequency is almost double in platelet function disorders compared with 
thrombocytopenias, ranging from 15.4% to 24.8% depending on the definition used. The frequency 
of AEB appeared to be especially high for some disorders, including bBSS, FPD/AML, GT and 
HPS, with up to 44.4% of the procedures eliciting excessive bleeding.  
Some of the findings of the present study provide novel and relevant clinical information on the 
bleeding risk associated with IPFDs. In fact, while a high bleeding risk of GT and bBSS is generally 
accepted, the high frequency of surgery-associated bleeding in HPS, FPD/AML, GPS and 
autosomal-dominant GT-variants was unexpected because they are commonly considered as non-
severe. However, it can not be excluded that AEB in these patients was due to the infrequent use of 
a preoperative prophylactic treatment probably consequent to the assessment of these disorders as 
mild. Other IPFDs too, like PT-VWD, TXA2 receptor defect and CalDAG-related platelet disorder, 
suffered frequent post-surgical bleedings, although this observation can be considered only as 
anecdotal given the scarce number of patients enrolled. On the other hand, other IPFDs showed a 
low bleeding risk, like collagen receptor defects, δ-granules deficiency and primary secretion 
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defects. Given that preoperative prophylaxis was administered in only 37.5% of the procedures in 
patients with collagen receptors defects, these seem indeed mild disorders. 
IPNDs were associated with infrequent surgical bleeding, ranging from 5.4% to 13.3% depending 
on definition, with no significant differences among the different disorders.  
Given that 21% of the enrolled patients were GT, and that a prophylactic treatment was 
administered in 90.7% of the procedures carried out in this patient subgroup, the impact of this on 
the overall analysis was evaluated by excluding the procedures carried out in GT. AEB in the 
remaining IPFD population was 21.9%, not significantly different from the 24.8% observed in the 
total IPFD population (p=ns by χ2). 
The same procedure was applied to IPNDs by excluding MYH9-RD: AEB in the remaining IPND 
population was 11.9%, not different from the 13.4% of the total IPND population (p=ns by χ2).  
In IPNDs 68 x109/L platelets was the threshold below which bleeding rate increased significantly, a 
value quite similar to that previously identified as predictive of bleeding at childbirth8. 
In the overall IPD population, bleeding history was highly predictive of surgical bleeding, in fact a 
WHO ≥2 was associated with an over than four-fold increased bleeding rate. Moreover, bleeding 
occurring after the first surgical procedure strongly predicted the rate of bleeding in subsequent 
procedures. 
Of note, bleeding tendency was higher in IPFDs than in IPNDs, with 79.8% of patients with a 
WHO grade 3 and 64.3% with a WHO grade 4 being IPFD8,9,32. Similarly, in the subgroup of 
patients for whom the ISTH BAT bleeding score was available this was highly predictive of post-
surgical bleeding, with a ISTH BAT ≥6 associated with a strongly increased bleeding risk. 
Some types of surgery were associated with higher bleeding, like cardiovascular or urologic surgery. 
On the other hand, also minor invasive procedures were associated with bleeding, suggesting that 
prophylactic measures need to be applied also to procedures such as a gastroscopy with biopsy. 
Administration of an anti-hemorrhagic prophylactic treatment was associated with a reduced 
bleeding frequency in the IPFD population but not in IPND. This seems to be reflected in the 
current practice, likely based on expert consultation, given that patients with IPFDs in our study 
were for the vast majority prophylaxed (80.6%), while patients with IPND were prophylaxed only 
occasionally (20.6%).  
The apparent lower efficacy of preoperative prophylaxis in IPND patients may derive from the 
lower absolute bleeding risk in this subpopulation, with consequent lower statistical power to detect 
reduced bleeding in prophylaxed subjects, and/or by the use of milder prophylactic measures (lower 
dosage, shorter duration, etc..) due to the perception of a lower bleeding risk. 
On the other hand, the choice of the preventive measures did not appear to be always appropriate, 
 13
since platelet transfusions, the most frequently used prophylactic treatment, revealed to be poorly 
effective, with bleeding occurring in 30.1% of the procedures in which they were used. These data 
are in agreement with previous findings in pregnancy8,9. However, it should be considered that 
platelet transfusions were most frequently used in patients with severe bleeding disorders and/or 
undergoing major surgery and that the mode of administration of platelet transfusions was rather 
heterogeneous and possibly sometimes incongruous. These observations suggest that the way 
platelet transfusions are employed (amount, type, timing) is often inappropriate33,34 
The most effective prophylactic treatment was desmopressin, alone or in combination with 
antifibrinolytic agents, while antifibrinolytic agents used alone were less effective. In particular, 
desmopressin was prophylactically employed in 88 procedures (10.3% minor invasive, 26.1% 
dental and 63.6% major procedures) only 6 of which were followed by AEB (7%), 4 of which 
(66.7%) after major surgeries and 2 (33.3%) dental procedures. Interestingly, 31.9% (28/88) of 
patients in whom DDAVP was employed had a severe bleeding history (WHO=3) and only 3 of 
them suffered AEB, data supporting the efficacy of this pro-haemostatic treatment for IPFDs, even 
for the more severe conditions. 
FVIIa, an approved treatment for GT, resulted to be a good prophylactic measure, in line with 
previous results25. In our cohort of patients FVIIa alone was prophylactically employed in 36 
patients, 32 of whom were GT. 55% of these patients had a WHO = 1 or 2, 33% had a WHO=3 and 
2.7% had a WHO=4 and underwent in 27.8% of cases to minor invasive procedures, 47.2% to 
dental procedures and in 25% to major procedures. These data suggest that FVIIa is efficacious also 
for severe cases and when used alone.  
Although we do not have data from the current study on the safety of the prophylactic measures, 
previous experience suggests that they are generally well tolerated. Mild adverse effects of 
desmopressin may include headache, nausea and hypotension, although sometimes more serious 
side effects, such as hyponatremia and renal dysfunction, may occur. After antifybrinolytic agents 
allergic or anaphylactic reactions and sometimes headache may occur. Finally, pro-hemostatic 
agents, and in particular recombinant FVIIa, may predispose to thrombotic complications, however 
the latter are relatively rare and depend on the thrombotic risk profile of the patient and the 
procedure5,35.  
Finally, treatment of surgical bleeding was successful in most IPFD cases (73.4%), and in a slightly 
lower number of IPND cases (58%).  
Our study has several limitations. First, it is retrospective, with all the inaccuracies in data 
collection that this may imply. However, the submitted questionnaire was strongly structured, with 
mandatory fields and pre-defined possible replies, ensuring a high degree of standardization; 
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moreover, the large number of patients and procedures collected strengthen the conclusions. Second, 
a comparative population of normal subjects undergoing the same invasive procedures would have 
provided a better quantification of the excess surgical bleeding risk. This was indeed planned in the 
study protocol, but it was impossible to collect enough control cases. However, for the few surgical 
procedures in healthy controls collected, frequency of post-surgical bleeding was strikingly lower 
(1/34; 3%), and similar to the estimated hemorrhagic complications rate of surgery (1.4% to 6%) in 
otherwise healthy subjects30,36. Third, for specific disorders, such as CalDAG-related platelet 
disorder, combined α/δ granule deficiency, and Scott syndrome, the exact bleeding risk could not 
be estimated, because only a few procedures were available, reflecting their rarity. However, our 
results provide a first useful hint of the surgical bleeding phenotype of these forms. Fourth, we do 
not have information about possible side effects of the pro-haemostatic procedures employed, about 
other concomitant factors that may have increased the risk of surgical bleeding (for example blood 
pressure, acquired coagulopathy, VWD, abnormalities of whole cell count).  
In conclusion, our study shows that surgery-related bleeding risk is substantial in IPDs, especially 
in IPFDs, that the bleeding history, some specific disorders and female gender are predictors of the 
bleeding risk, and that some types of invasive procedures are at particularly high risk. Importantly, 
prophylactic treatment is associated with a significant reduction of the bleeding frequency in IPFDs.  
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Table 1. Diagnosis and features of included patients  
 





Glanzmann thrombasthenia 89 (37.4) 53.9 33 (19-47) 245 (172-297) 3 (2-4) 
Primary  secretion defect 46 (19.3) 56.5 29 (14-46) 219 (160-272) 1.5 (1-3) 
Bernard-Soulier Syndrome (biallelic) 17 (7.1) 58.8 34 (21-49) 33 (20-39) 3 (2-3) 
Delta granule deficiency 17 (7.1) 82.3 50 (37-59) 197 (141-232) 2 (1.75-3) 
Hermansky–Pudlak syndrome 11 (4.6) 54.5 31 (24-50) 261 (228-321) 2 (1-2.5) 
Gray platelet syndrome 10 (4.2) 30 31 (21-58) 65 (56-85) 2 (2-2) 
Autosomal dominant GT-variant 10 (4.2) 90 45 (42-53) 85 (62-110) 1 (0.25-2) 
Familial platelet disorder and predisposition to 
acute myelogenous leukemia 8 (3.4) 50 38 (24-51) 102 (93-139) 2 (1.75-2.25) 
Defects in α2-adrenergic receptor 6 (2.5) 33.3 19 (11-43) 178 (146-239) 1 (0.25-1.75) 
Defects in collagen receptors 5 (2.1) 60 30 (23-59) 184 (126-256) 1 (0-2) 
P2Y12 deficiency 5 (2.1) 40 36 (27-78) 190 (183-195) 2 (2-2) 
Platelet-type Von Willebrand Disease 4 (1.7) 100 41 (31-52) 130 (113-168) 3 (2.75-3) 
Defect of thromboxane A2 receptor 3 (1.3) 66.7 33 (29-52) 166 (129-169) 2 (2-2.5) 
Scott syndrome 3 (1.3) 100 74 (58-75) 340 (-)* 1.5 (0.75-3) 
CalDAG-related platelet disorder 2 (0.8) 50 54 (53-56) 267 (251-284) 3 (3-3) 
Combined alpha-delta granule deficiency 2 (0.8) 50 52 (44-61) 85 (78-92) 0 (0-0) 
TOTAL  238 (56.3% of 423) 58 36 (20-50) 191.5 (113-266) 2 (1-3) 
      
IPND N (% of total) Females (%) AGE (median-IQR) Platelet count (x10
9/L) 
(median-IQR) median (IQR) 
MYH9-related disease  75 (40.5) 57.3 41 (31-56) 38 (22-50) 1 1 (0-2) 
ANKRD26-related thrombocytopenia  39 (21.1) 41 48 (38-67) 40 (29-54) 2 1 (0-2) 
Bernard-Soulier Syndrome (monoallelic) 34 (18.4) 61.7 49 (42-60) 82 (61-105) 3 1 (0-2) 
ACTN1-related thrombocytopenia 17 (9.2) 76.4 43 (35-51) 93 (72-118)4 1 (0-2) 
X-linked thrombocytopenia 7 (3.8) 0 29 (16-36) 34 (24-34) 1 (1-2) 
Thrombocytopenia with absent radii  5 (2.7) 40 26 (17-30) 20 (16-31) 2 (0-2) 
Paris-Trousseau thrombocytopenia 4 (2.2) 25 12 (7-16) 52 (18-115) 0.5 (0-1) 
Congenital amegakaryocytic 
thrombocytopenia 2 (1.1) 50 9 (6-11) 61 (61-61) 1 (1-1) 
FLNA-related thrombocytopenia  2 (1.1) 100 40 (33-47) 34 (29-38) 5 1 (0.5-1.5) 
TOTAL 185 (43.7% of 423) 53.5 43 (32-59) 50 (30-81) 1 (0-2) 
  Platelet count microscopic (x109/L): 155 (36-72); 250 (33-70); 391 (82-121.5); 4110 (93-129); 555.5 (47.25-63.75). * only one count available 
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Table 2.  Characteristics of surgical procedures according to diagnosis.  
 
IPFD N (% of total) AGE at surgery (median-IQR) major surg (%) minor surg (%) dental proc (%) 
Glanzmann thrombasthenia 182 (40) 31 (13-50) 43.9 15.4 40.7 
Primary  secretion defect 76 (16.7) 26 (8-40) 69.7 10.5 19.7 
Bernard-Soulier Syndrome (biallelic) 36 (7.9) 30 (16-49) 52.8 19.4 27.8 
Delta granule deficiency 36 (7.9) 50 (35-55) 72.2 13.9 13.9 
Hermansky–Pudlak syndrome 22 (4.8) 16 (12-24) 63.6 18.2 18.2 
Autosomal dominant GT-variant 22 (4.8) 23 (11-33) 63.6 0 36.4 
Gray platelet syndrome 17 (3.7) 60 (22-69) 52.9 23.5 23.5 
Defects in collagen receptors 16 (3.5) 10 (7-47) 56.2 12.5 31.2 
Familial platelet disorder and predisposition to acute 
myelogenous leukemia 13 (2.8) 28 (20-48) 61.5 23.1 15.4 
Defects in α2-adrenergic receptor 9 (1.9) 36 (22-44) 44.4 22.2 33.3 
P2Y12 deficiency 9 (1.9) 73 (72-76) 33.3 66.7 0 
Defect of thromboxane A2 receptor 5 (1.1) 24 (21-30) 80 0 20 
Platelet-type Von Willebrand Disease 5 (1.1) 34 (30-38) 40 40 20 
Scott syndrome 3 (0.7) 74 (73-76) 66.7 33.3 0 
CalDAG-related platelet disorder 2 (0.4) 30 (28-31) 50 0 50 
Combined alpha-delta granule deficiency 2 (0.4)  -  0 50 50 
TOTAL 455 (54.9% of 829) 31 (15-52) 54.5 16 29.5 
      
IPND N (% of total) AGE at surgery (median-IQR) major surg (%) minor surg (%) dental proc (%) 
MYH9-related disease 148 (39.6) 28 (12-47) 64.9 6.7 28.4 
ANKRD26-related thrombocytopenia 89 (23.8) 35 (19-50) 70.8 2.2 26.9 
Bernard-Soulier Syndrome (monoallelic) 74 (19.8) 34 (20-51) 67.6 12.2 20.3 
ACTN1-related thrombocytopenia 39 (10.4) 30 (9-44) 66.7 10.3 23.1 
X-linked thrombocytopenia 9 (2.4) 20 (17-26) 44.4 0 55.5 
Thrombocytopenia with absent radii 6 (1.6) 16 (10-27) 50 33.3 16.7 
Paris-Trousseau thrombocytopenia 5 (1.3) 1 (1-4) 80 0 20 
Congenital amegakaryocytic thrombocytopenia 2 (0.5) 8 (6-11) 50 50 0 
FLNA-related thrombocytopenia 2 (0.5) 23 (17-28) 0 0 100 








PT=Platelet transfusion; AA= Antifibrinolytic agents; Other: cryoprecipitate; fibrin-glue. fibrinogen. FFP. IVIG. local hemostatic agent. suture. local tranexamic acid 









 IPD IPFD IPND Major surg Minor surg Dental proc 
  Prophylaxis N (%) % AEB N (%) % AEB N (%) % AEB N (%) % AEB N (%) % AEB N (%) % AEB 
None 355 (42.8) 19.7 88 (19.3) 40.9 267 (71.4) 12.7 232 (46.9) 20.8 27 (26.7) 21.4 96 (41.2) 16.7 
Any: 474 (57.2) 19.6 367 (80.7) 20.9 107 (28.6) 14.9 263 (53.1) 22.8 74 (73.3) 24.3 137 (58.8) 10.9 
- PT 199 (24) 26.3 122 (26.8) 31.4 77 (20.5) 18.2 137 (27.7) 29.2 33 (32.7) 33.3 29 (12.4) 3.6 
- AA 66 (8) 15.1 51 (11.2) 17.6 15 (4) 6.7 15 (3.0) 6.7 12 (11.9) 33.3 39 (16.7) 12.8 
- PT+AA 61 (7.4) 16.1 56 (12.3) 17.5 5 (1.3) 0 30 (6.1) 20.0 8 (7.9) 25.0 23 (9.9) 8.3 
- DDAVP 41 (4.9) 7.3 37 (8.1) 8.1 4 (1.1) 0 17 (3.4) 17.6 8 (7.9) 0 16 (6.9) 0 
- DDAVP+AA 36 (4.3) 8.3 36 (7.9) 8.3   31 (6.3) 3.2    5 (2.1) 40.0 
- FVIIa 27 (3.3) 18.5 27 (5.9) 18.5   7 (1.4) 14.3 9 (8.9) 11.1 11 (4.7) 27.3 
- Other 17 (2.1) 35.3 11 (2.4) 45.4 6 (1.6) 16.7 12 (2.4) 33.3 2 (2.0) 0 3 (1.3) 66.7 
- PT+AA+DDAVP 8 (1) 0 8 (1.7) 0   6 (1.2) 0   2 (0.9) 0 
- FVIIa+AA 7 (0.8) 14.3 7 (1.5) 14.3   1 (0.2) 100 1 (1.0) 0 5 (2.1) 0 
- PT+ Other 4 (0.5) 50.0 4 (0.9) 50.0   3 (0.6) 66.7   1 (0.4) 0 
- AA+Other 3 (0.4) 33.3 3 (0.7) 33.3   1 (0.2) 100     
- PT+DDAVP 2 (0.2) 0 2 (0.4)    2 (0.4) 0     
- FVIIa+AA+ 
Other 1 (0.1) 0 1 (0.2)       1 (1.0) 0   
- PT+DDAVP+ 
Other 1 (0.1) 0 1 (0.2)        1 (0.4) 0 
- PT+FVIIa 1 (0.1) 0 1 (0.2)    1 (0.2) 0     
TOTAL 829 19.66 455 24.84 374 13.37 495 21.86 101 23.53 233 13.30 
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Table 4. Prophylactic treatments according to diagnosis.  
         
IPFD 
Prophylaxed/total 















Glanzmann thrombasthenia  155/182 (90.7) 54 (34.8) 30 (19.3) 35 (22.6) 6 (3.9)  (0) 24 (15.5) 6 (3.9) 
Primary secretion defect 62/76 (85.5) 9 (14.5) 9 (14.5) 6 (9.7) 15 (24.2) 23 (37.1)  (0)  (0) 
Bernard-Soulier Syndrome (biallelic) 34/36 (97.2) 26 (76.5) 1 (2.9) 3 (8.8) 1 (2.9) 2 (5.9)  (0) 1 (2.9) 
Delta granule deficiency  25/36 (83.3) 2 (8) 3 (12) 6 (24) 5 (20) 9 (36)  (0)  (0) 
Hermansky–Pudlak syndrome  11/22 (50) 4 (36.4) 1 (9.1) 1 (9.1) 4 (36.4)  (0) 1 (9.1)  (0) 
ITGA2B/ITGB3-related thrombocytopenia 6/22 (36.4) 2 (33.3) 2 (33.3) 2 (33.3)  (0)  (0)  (0)  (0) 
Gray platelet syndrome  12/17 (70.6) 8 (66.7) 2 (16.7)  (0)  (0) 1 (8.3)  (0) 1 (8.3) 
Defects in collagen receptors 6/16 (37.5)  (0) 1 (16.7)  (0) 2 (33.3)  (0) 1 (16.7) 2 (33.3) 
Familial platelet disorder and predisposition to acute 
myelogenous leukemia  6/13 (61.5) 4 (66.7) 1 (16.7) 1 (16.7)  (0)  (0)  (0)  (0) 
Defects in α2-adrenergic receptor 7/9 (77.8) 3 (42.9) 1 (14.3) 1 (14.3) 2 (28.6)  (0)  (0)  (0) 
P2Y12 deficiency  7/9 (77.8) 5 (71.4)  (0)  (0) 1 (14.3)  (0)  (0) 1 (14.3) 
Defect of thromboxane A2 receptor 3/5 (60)  (0)  (0) 1 (33.3) 1 (33.3) 1 (33.3)  (0)  (0) 
Platelet-type Von Willebrand Disease  1/5 (40) 1 (100)  (0)  (0)  (0)  (0)  (0)  (0) 
Scott syndrome  3/3 (100) 2 (66.7)  (0)  (0)  (0)  (0) 1 (33.3)  (0) 
CalDAG 2/2 (100) 2 (100)  (0)  (0)  (0)  (0)  (0)  (0) 
Combined alpha-delta granule deficiency 0/2 (0)               
TOTAL 455 (80.7) 122 51 56 37 36 27 11 
         
IPND 
Prophylaxed/total 






 (%) DDAVP (%) 
DDAVP
+AA (%) FVIIa (%) 
Other 
(%) 
MYH9-related disease  53/148 (35.8) 42 (79.2) 8 (15.1)     3 (5.6) 
ANKRD26-related thrombocytopenia  24/89 (27) 18 (75) 1 (0.4) 1 (0.4) 3 (12.5)   1 (0.4) 
Bernard-Soulier Syndrome (monoallelic) 13/74 (17.6) 7 (53.8) 5 (38.5)     1 (7.7) 
ACTN1-related thrombocytopenia  0/39 (0)        
X-linked thrombocytopenia 6/9 (66.7) 2 (33.3)  3 (50)    1 (16.7) 
Thrombocytopenia with absent radii  4/6 (66.7) 3 (75)  1 (25)     
Paris-Trousseau thrombocytopenia 5/5 (100) 3 (60) 1 (20)  1 (20)    
Congenital amegakaryocytic thrombocytopenia 2/2 (100) 2 (100)       
FLNA-related thrombocytopenia  0/2 (0)        
TOT 374 (28.6) 77 15 5 4   6 
Prophylactic treatments with sample size <10 not shown. PT=Platelet transfusion; AA=Antifibrinolytic agents; Other: cryoprecipitate; fibrin-glue. fibrinogen. FFP. IVIG. local 
hemostatic agent. suture. local tranexamic acid (for IPFD); Eltrombopag. fresh frozen plasma. IVIG. local hemostatic agent. prophylactic surgical haemostasis (for IPND).
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Table 5. Incidence of bleeding in the different IPD populations according to the type of surgery. 
 
 
IPD IPFD IPND IPFD vs IPND Χ2 
Procedure N (% AEB) N (% AEB) N (% AEB) p-value 
DENTAL PROCEDURES 233 (13.3) 134 (15.7) 99 (10.1)  
MINOR SURGERY:     
Cyst/abscess drainage 5 (60) 3 (66.7) 2 (50) ns 
Central catheter placement 11 (36.4) 9 (44.4) 2 (0) ns 
Hemorrhoidectomy 8 (25) 3 (33.3) 5 (20) ns 
Invasive Procedure 25 (20) 15 (26.7) 10 (10) ns 
Colonoscopy 25 (20) 21 (23.8) 4 (0) ns 
Gastroscopy 11 (18.2) 10 (20) 1 (0) ns 
Biopsy 17 (17.6) 13 (23.1) 4 (0) ns 
TOT minor surgery 102 (23.5) 74 (28.4) 28 (10.7)   
MAJOR SURGERY:      
Thoracic Surgery 2 (50) 2 (50)  ns  
Cardiovascular Surgery 17 (47.1) 9 (77.8) 8 (12.5) 0.02 
Urological Surgery 38 (34.2) 24 (37.5) 14 (28.6) ns  
Neurological Surgery 7 (28.6) 5 (20) 2 (50) ns  
Gynecological Surgery 56 (26.8) 31 (35.5) 25 (16) ns  
Otorinolaringologic Surgery 106 (24.5) 49 (24.5) 57 (24.6) ns  
Plastic Surgery 14 (21.4) 4 (25) 10 (20) ns  
Eye Surgery 25 (20) 12 (41.7) 13 (0) 0.03 
Abdominal Surgery 126 (19.8) 52 (30.8) 74 (12.2) 0.01 
Orthopedic Surgery 56 (12.5) 30 (16.7) 26 (7.7) ns  
Breast Surgery 13 (7.7) 7 (14.3) 6 (0) ns  
Dermatologic Surgery 34 (5.9) 22 (9.1) 12 (0) ns  
TOT major surgery 494 (21.9) 247 (28.7) 247 (15) 0.0003 
TOT 829 (19.7) 455 (24.8) 374 (13.4) 0.0001 









Table 6. Univariate and multivariate logistic analyses of factors associated with surgical bleeding.  
 
 IPFD (n=455)  IPND (n=374) 
 
Univariate analysis 
OR (95% CI) 
Multivariate analysis 
OR (95% CI) 
 Univariate analysis 
OR (95% CI) 
Multivariate analysis 
OR (95% CI) 
Female gender 1.8 (1.1-2.9) 1.28 (2.13-0.76)  - - 
WHO bleeding score      
- Grade 0 1.00 1.00  1.00 1.00 
- Grade 1 0.91 (0.17-4.97) 1.29 (0.23-7.35)  4.27 (1.34-13.57)  
- Grade 2 3.87 (0.87-17.17) 4.96 (1.08-22.82)  5.16 (1.69-15.79)  
- Grade 3 6.62 (1.52-28.89) 8.47 (1.83-39.13)  10.9 (3.28-36.25)  
- Grade 4 10 (1.8-55.53) 19.23 (3.23-114.55)  20.44 (3.38-123.53)  
Platelet count <68x109/L - -  2.04 (1.01-4.12)  
Age ≥ 70 years    1.84 (1.009-3.37)  





















Figure 1. Frequency of prophylactic treatments according to WHO bleeding score and 
platelet count. 
A) Use of prophylactic preoperative treatments according to preoperative WHO bleeding score 
in the overall IPD population, in IPFDs and IPNDs. 
B) Use of prophylactic preoperative treatments according to preoperative platelet count 
quartiles (x109/L) (microscopic) in IPNDs.  
 
Figure 2. Post-surgical bleeding in IPD. 
A) Incidence of bleeding (AEB) in the overall IPD population, in IPFD and in IPND according 
to pre-surgical WHO bleeding score. 










This study was promoted by the Scientific Working Group (SWG) on Thrombocytopenias and 
Platelet Function Disorders of the European Hematology Association (EHA). The Institutional 
Review Board of the coordinating center (CEAS Umbria, Italy) approved the study, the study was 
performed in accordance with the Declaration of Helsinki, each center complied with local ethical 
rules and all patients or their legal representatives signed a written informed consent. 
Clinical centers that, based on scientific publications and/or personal knowledge, represent 
reference centers for IPDs were invited to participate. Moreover, the EHA launched a public call to 
participate in the study in April 2014 and all the investigators that previously participated in two 
large international studies on the diagnosis of platelet function disorders were also personally 
contacted
3,8,9
. Participating investigators were asked to review their records and extract data on 
surgery and invasive procedures carried out in patients with IPDs over the last years (median 8; 
IQR 4-18 years) and to obtain additional data directly from the surgeon who carried out the 
intervention or, in case this was not possible, from the patient or his/her relatives. A series of 
structured questions had to be answered for each enrolled case concerning the characteristics of the 
patient, type of surgery, and preparation to and outcome of surgery, with particular attention to post 
surgical bleeding, its management and outcome. Only patients with a definite diagnosis of IPD 
confirmed according to well-defined laboratory and/or molecular genetic criteria
6,8,9
, 
(supplementary table 1-2) were eligible for the study. IPDs were subdivided in IPNDs, when low 
platelet count was the main phenotypic characteristic (e.g. MYH9-RD), and IPFDs, when platelet 
dysfunction was the dominant phenotypic feature, independently of platelet count (e.g. autosomal 
dominant GT-variant) (Table 1). Patients with acquired platelet disorders of any etiology were 
excluded. All types of surgical procedures, including invasive diagnostic procedures (e.g. 
angiography, endoscopic and tissue biopsies) and dental extractions, were included. Caesarian 
sections were excluded because analyzed in a previous study
8,9
.  
Surgical procedures were categorized post hoc as major surgery, minor invasive procedures and 
dental procedures according to the following criteria: major, any procedure in which a body cavity 
was entered, a mesenchymal barrier was crossed, a facial plane was opened, an organ was removed 
or normal anatomy was altered; minor invasive, any operative procedure in which only skin, 
mucous membranes or superficial connective tissue were manipulated, gastroscopy, colonoscopy 





Classification of bleeding 
Bleeding history was assessed by the World Health Organization (WHO) bleeding assessment 
scale
29
 and, when available, by the ISTH bleeding score scale
30
. Severity of surgical bleeding was 
defined according to three different criteria. One was the bleeding academic research consortium 
(BARC) classification, which is based on a score from 0 to 5 where 0 indicates absence of bleeding 
and 5 fatal bleeding. We considered as excessive any bleeding to which a BARC ≥ 2 was 
assigned
31
. Another was the classification of bleeding based on a subjective evaluation from the 
surgeon or, when not available, from the patient as “excessive” or “normal
 8,9
. The third the duration 
(from less than 6 hours to more than 3 days), considered as excessive when >6 hours. Procedures 
associated with excessive bleeding according to any of the above three criteria, were classified as 
any excessive bleeding (AEB). 
When available, maximal drop of hemoglobin after surgery (g/dl) and volume of blood lost 
(ml/24hours) were registered. Finally, outcome of treatment of surgical bleeding was classified as 






























Supplemental Table 1. Laboratory and/or molecular genetic criteria required for a definite 
diagnosis of IPND. 
 





X-linked thrombocytopenia (XLT. 313900) XL WAS (Xp11) Genetic analysis 
MYH9-related disease (MYH9-RD. nd) AD MYH9 (22q12-13) 
Genetic analysis or positive 
immunofluoresce screening test or 
Döhle-like bodies 
Paris-Trousseau thrombocytopenia (TCPT. 
188025/600588). Jacobsen syndrome (JBS. 
147791) 
AD Large deletion (11q23-ter) Genetic analysis 
Thrombocytopenia with absent radii (TAR. 
274000) 
AR RBM8A (1q21.1) Genetic analysis or typical phenotype 
Congenital thrombocytopenia with radio-ulnar 
synostosis (CTRUS. 605432) 
AD HOXA11 (7p15-14) Genetic analysis or typical phenotype 
Thrombocytopenia associated with sitosterolaemia 
(STSL. 210250) 
AR ABCG5. ABCG8 (2p21) Genetic analysis  
NON-SYNDROMIC FORMS 
Biallelic AR 
Genetic analysis or absent GPIb/IX/V 
or absent RIPA Bernard-Soulier syndrome 
(BSS. 231200) 
Monoallelic AD 
GP1BA (17p13). GP1BB 
(22q11). GP9 (3q21) 
Genetic analysis 
Familial platelet disorder and predisposition to 
acute myelogenous leukemia (FPD/AML. 601399) 
AD RUNX1 (21q22) Genetic analysis 
ANKRD26-related thrombocytopenia (THC2. 
313900) 







TUBB1-related thrombocytopenia (TUBB1-RT. 
613112) 
AD TUBB1 (6p21.3) Genetic analysis 
CYCS-related thrombocytopenia (THC4. 612004) AD CYCS (7p15.3) Genetic analysis 
Congenital amegakaryocytic thrombocytopenia 
(CAMT. 604498) 
AR MPL (1p34) Genetic analysis or typical phenotype 
GATA1-related diseases (GATA1-RDs. 
Dyserythropoietic anemia with thrombocytopenia. 
300367 – X-linked thrombocytopenia with 
thalassemia. 314050) 
XL GATA1 (Xp11) Genetic analysis  
ACTN1-related thrombocytopenia (ACTN1-RT. nd) AD ACTN1 (14q24) Genetic analysis  
FLNA-related thrombocytopenia (FLNA-RT. nd) XL FLNA (Xq28) Genetic analysis  
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Supplemental Table 2. Laboratory and/or molecular genetic criteria required for a definite 
diagnosis of IPFD. 
 



















Genetic analysis or typical phenotype + 
delta granule deficiency or decrease in 
platelet nucleotide content and increased 
ATP/ADP ratio (+decreased 5HT 
content) 
NON SYNDROMIC FORMS 





Genetic analysis or absent platelet 
aggregation or absent GPIIb-IIIa 
P2Y12 deficiency (nd. 609821) AR 
P2RY12  (3q24-
q25) 
Genetic analysis or selective. severe 
defect of platelet aggregation by ADP. 
defect of inhibition o adenylyl cyclase 
by ADP (VASP phosphorylation assay) 
Defect of thromboxane A2 receptor 
(nd. 188070) 
AD TBXA2R (19p13.3) 
Genetic analysis or defective platelet 
aggregation induced by U46619 and by 
arachidonic acid 




Quebec platelet disorder (QPD. 
601709) 
AD PLAU (10q24) Genetic analysis 
Delta granule deficiency  AR/AD Unknown 
Absence of delta-granules (TEM) or 
decrease in platelet nucleotide content 
and increased ATP/ADP ratio 
(+decreased 5HT content) 
Combined alpha-delta granule 
deficiency (nd. 185050) 
AR/AD Unknown 
Severe deficiency of alpha and delta 
granules 
Platelet-type Von Willebrand Disease 
(VWDP. 177820) 
AD GP1BA (17p13.2) Genetic analysis 
Gray platelet syndrome (GPS. 139090) AR NBEAL2 (3p21.1)  
Genetic analysis or absence of alpha-
granules 
Gray platelet syndrome with mutation 
in GFI1B 
AD GFI1B (9q34.13) Genetic analysis 
Primary  secretion defect (nd. nd) 
 
AR/AD Unknown 
Reduced primary platelet granule 
secretion upon stimulation by different 
platelet aggregation agonists. normal 
TxB2 production induced by AA (or 
serum TxB2) and normal granule 
content. 
Defects in collagen receptors (nd. nd) AR Unknown 
Defective platelet aggregation in the 
response to collagen 
 
 














COX-1 deficiency AD Unknown 
Defective aggregation in response to 
arachidonic acid; defective serum TXB2;  




Tx synthase deficiency AD TBXAS1 (7q34) Genetic analysis 
PKC deficiency unknown Unknown 
Defective aggregation in response to 




Supplemental Table 3. Incidence of bleeding according to definition and diagnosis.  
 
IPFD AEB BARC        Subjective evaluation Duration >6h 
Diagnosis 
AEB/total  
(% of total)  
0 1 2 3a 3b 4 5a 5b % >=2 N (% of total)  N (% of total)  
Defect of thromboxane A2 receptor 4/5 (80) 2 0 1 2 0 0 0 0 60 3 (60) 5 (60) 
Platelet-type Von Willebrand Disease 4/5 (80) 1 0 2 2 0 0 0 0 80 3 (60) 5 (40) 
CalDAG-related platelet disorder 1/2 (50) 0 1 1 0 0 0 0 0 50 1 (50) 2 (50) 
Bernard-Soulier Syndrome (biallelic)* 16/36 (44) 15 9 11 1 0 0 0 0 33.3 7 (19.4) 36 (41.7) 
Familial platelet disorder and predisposition to 
acute myelogenous leukemia* 
4/13 (30.8) 8 3 2 0 0 0 0 0 15.4 4 (30.8) 13 (15.4) 
Glanzmann thrombasthenia* 53/182 (29.1) 102 34 19 19 5 2 0 0 24.7 37 (20.3) 167 (15) 
Hermansky–Pudlak syndrome* 6/22 (27.3) 13 3 3 1 2 0 0 0 27.3 5 (22.7) 21 (19) 
Gray platelet syndrome* 4/17 (23.5) 12 2 2 1 0 0 0 0 17.6 2 (11.7) 17 (0) 
Autosomal dominant GT-variant* 5/22 (22.7) 15 2 2 2 0 0 0 0 18.2 5 (22.7) 19 (10.5) 
Defects in α2-adrenergic receptor 2/9 (22.2) 7 0 1 0 1 0 0 0 22.2 2 (12.5) 16 (0) 
Defects in collagen receptors* 2/16 (12.5) 13 2 1 0 0 0 0 0 6.2 2 (22.2) 9 (22.2) 
Delta granule deficiency* 4/36 (11.1) 29 3 2 1 0 0 0 0 8.3 4 (11.1) 36 (11.1) 
Primary  secretion defect* 8/76 (10.5) 66 3 5 1 1 0 0 0 9.2 7 (9.2) 76 (9.2) 
Combined alpha-delta granule deficiency 0/2 (0) 2 0 0 0 0 0 0 0 0 0 (0) 2 (0) 
P2Y12 deficiency 0/9 (0) 8 0 0 0 0 0 0 0 0 0 (0) 9 (0) 
Scott syndrome 0/3 (0) 3 0 0 0 0 0 0 0 0 0 (0) 3 (0) 
TOTAL 113 (24.8) 296 62 52 30 9 2 0 0 20.4 82 (18) 436 (15.4) 
             
IPND 
AEB/total  
(% of total) 
BARC     
 
  Subjective evaluation 
Duration >6h 
Diagnosis N (% of total)  0 1 2 3a 3b 4 5a 5b % >=2 N (% of total)  N (% of total)  
FLNA-related thrombocytopenia 1/2 (50) 1 1 0 0 0 0 0 0 0 1/2 (50) 1/2 (50) 
X-linked thrombocytopenia 2/92 (22.2) 5 2 1 0 0 0 0 0 11.1 2/92 (22.2) 2/92 (22.2) 
Paris-Trousseau thrombocytopenia 1/5 (20) 4 0 0 1 0 0 0 0 20 1/5 (20) 1/5 (20) 
MYH9-related disease* 23/148 (15.5) 119 13 11 3 0 0 0 1 10.1 20/148 (13.5) 3/148 (2.1) 
ACTN1-related thrombocytopenia* 5/39 (12.8) 34 1 3 0 1 0 0 0 10.3 5/39 (12.8) 2/39 (5.1) 
ANKRD26-related thrombocytopenia* 10/89 (11.2) 74 5 7 1 0 0 0 0 9 10/89 (11.2) 7/89 (7.9) 
Bernard-Soulier Syndrome (monoallelic) * 8/74 (10.8) 65 4 3 1 1 0 0 0 6.7 6/74 (8.1) 4/74 (5.4) 
Congenital amegakaryocytic thrombocytopenia 0/2 (0) 1 1 0 0 0 0 0 0 0 0/2 (0) 0/2 (0) 
Thrombocytopenia with absent radii 0/6 (0) 4 2 0 0 0 0 0 0 0 0/6 (0) 0/6 (0) 
TOTAL 50 (13.4) 307 29 25 6 2 0 0 1 9.1 45 (12) 370 (5.4) 
*Disorders with more than 10 procedures 
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Supplemental table 4. Treatment of post-surgical bleeding according to disease group and type of surgery.  
 
 IPD IPFD IPND Major surg Minor surg Dental proc 
Treatment 
N/total (% of 
total) 
N (% of total) N (% of total) N (% of total) N (% of total) N (% of total) 
PT 56 (34.4) 44 (38.9) 12 (24) 43 (39.8) 8 (33.3) 5 (16.1) 
Ot 23 (14.1) 10 (8.8) 13 (26) 12 (11.1) 2 (8.3) 9 (29) 
AA 22 (13.5) 16 (14.2) 6 (12) 10 (9.3) 3 (12.5) 9 (29) 
PT+FVIIa 10 (6.1) 10 (8.8)  8 (7.4) 2 (8.3)  
FVIIa 6 (3.7) 6 (5.3)  2 (1.9) 2 (8.3) 2 (6.5) 
PT+AA 5 (3.1) 5 (4.4)  4 (3.7) 1 (4.2)  
AA+DDAVP 2 (1.2) 2 (1.8)   1 (4.2) 1 (3.2) 
PT+FVIIa+AA 2 (1.2) 2 (1.8)   2 (8.3)  
AA+Ot 1 (0.6) 1 (0.9)   1 (4.2)  
AA+PT+Ot 1 (0.6) 1 (0.9)  1 (0.9)   
DDAVP 1 (0.6) 1 (0.9)  1 (0.9)   
none 34 (20.9) 15 (13.3) 19 (38) 27 (25.0) 2 (8.3) 5 (16.1) 
TOTAL 163  113  50  108  24  31  
 
PT=Platelet transfusion; AA=Antifibrinolytic agents; Ot=other: cryoprecipitate; fibrin-glue. fibrinogen. FFP. IVIG. local hemostatic agent. suture. local tranexamic acid 






Supplemental Figure 1. WHO bleeding score distribution of the enrolled IPD population.  
The WHO bleeding score is reported for the overall IPD population and separately for IPFDs and 
IPNDs (IPDs; n=423; IPFDs; n=238; IPNDs; n=185). 
 








































Supplemental Figure 2. Post-surgical bleeding in IPD. 
Percentage of total procedures (IPD=829; IPFD=455; IPND=374) followed by excessive bleeding 
according to the different definition criteria: AEB= any excessive bleeding; BARC≥2= any 
bleeding to which a BARC≥2 was assigned; subjective evaluation= bleeding classified as 
“excessive” or “normal” based on a subjective evaluation by the surgeon or when this was not 








AEB BARC ≥2 subjective
evaluation
duration ≥6h
IPD
IPFD
IPND
%
 o
t
to
ta
l 
p
ro
c
ed
u
re
s
Definition criteria
 
 
 
 
 
